About
Biosimilars
Areas of Focus
Categories
BiosimilarsNJ, NY, PA
Team (9)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
1,828
By Phase
PHASE1: 7PHASE3: 1
By Status
COMPLETED: 5NOT_YET_RECRUITING: 1RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06995482Lead Sponsor
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
PHASE1Not yet recruiting
40 participants
Started: May 31, 2025 · Completed: Apr 30, 2026
NCT06929052Lead Sponsor
A Open Label ,Randomized, Balanced, Two-treatment, Single Period, Parallel, Comparative Pharmacokinetic Study in Healthy Subjects
PHASE1Recruiting
150 participants
Started: Jan 29, 2025 · Completed: Jul 15, 2025
NCT06918587Lead Sponsor
Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study
PHASE1Active, not recruiting
180 participants
Started: Sep 5, 2024 · Completed: Apr 30, 2025
NCT06929039Lead Sponsor
Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects
PHASE1Completed
300 participants
Started: Jul 4, 2024 · Completed: Feb 25, 2025
NCT05774639Lead Sponsor
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
PHASE3Completed
600 participants
Started: Aug 15, 2023 · Completed: Dec 31, 2024
Locations (1)
Headquarters
Piscataway, NJ, United States
Map
Loading map...